Equities Analysts Issue Forecasts for DNLI FY2026 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at HC Wainwright raised their FY2026 earnings per share estimates for Denali Therapeutics in a research note issued on Tuesday, January 7th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.58) for the year, up from their previous estimate of ($0.69). HC Wainwright currently has a “Buy” rating and a $87.00 target price on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2027 earnings at $1.82 EPS.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the previous year, the business earned ($0.72) earnings per share.

Several other analysts have also issued reports on DNLI. Baird R W upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday. Robert W. Baird began coverage on Denali Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $31.00 target price on the stock. William Blair assumed coverage on Denali Therapeutics in a report on Friday, January 3rd. They issued an “outperform” rating for the company. Raymond James reissued a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Finally, Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Monday, December 16th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.91.

Denali Therapeutics Trading Up 0.3 %

Shares of Denali Therapeutics stock opened at $21.25 on Thursday. The company has a market cap of $3.06 billion, a price-to-earnings ratio of -7.70 and a beta of 1.39. Denali Therapeutics has a 1 year low of $14.56 and a 1 year high of $33.33. The company’s fifty day simple moving average is $24.23 and its 200-day simple moving average is $24.86.

Institutional Investors Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CWM LLC lifted its position in shares of Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after purchasing an additional 654 shares in the last quarter. Quest Partners LLC acquired a new position in Denali Therapeutics during the 3rd quarter worth $73,000. Assetmark Inc. boosted its position in Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after buying an additional 580 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Denali Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after buying an additional 920 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Denali Therapeutics during the second quarter worth $194,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Insider Transactions at Denali Therapeutics

In other news, Director Vicki L. Sato sold 1,020 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total transaction of $30,600.00. Following the sale, the director now owns 111,056 shares in the company, valued at approximately $3,331,680. This represents a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steve E. Krognes sold 3,339 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the completion of the transaction, the director now directly owns 25,757 shares of the company’s stock, valued at $536,003.17. This represents a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 104,518 shares of company stock valued at $2,576,982. 7.90% of the stock is owned by insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.